| 131. |
Desjardins A., Quinn J.A., Rich J.N., Vredenburgh J.J., Sathornsumetee S., Gururangan S., Friedman A.H., Berg W., Egorin M.J., Salvado A., Friedman H.S., Reardon D.A.
A phase I trial of imatinib (GLEEVEC), hydroxyurea and RAD001 for patients with recurrent malignant glioma.
Neuro-Oncology.
2006.
8
Journal Name : Neuro-Oncology
Source : ISI
|
| 132. |
Desjardins A., Reardon D.A., Quinn J.A., Rich J.N., Vredenburgh J.J., Sathornsumetee S., Salvado A., Friedman H.S.
Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas.
Journal of Clinical Oncology.
2006.
24
76S-76S.
Journal Name : Journal of Clinical Oncology
Source : ISI
|
| 133. |
Desjardins A., Vredenburgh J., Quinn J., Rich J., Sathornsumetee S., Friedman A., Reardon D., Friedman H.
Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide or irinotecan as an upfront treatment in patients with malignant glioma: Study of cases.
Neuro-Oncology.
2006.
8
Journal Name : Neuro-Oncology
Source : ISI
|
| 134. |
Desjardins, A; Vredenburgh, J; Quinn, J; Rich, J; Sathornsumetee, S; Gururangan, S; Friedman, A; Reardon, D; Friedman, H.
Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and chemotherapy for recurrent malignant glioma patients: Series of cases.
Neuro-Oncology.
2006.
8
Journal Name : Neuro-Oncology
Source : ISI
|
| 135. |
Di Legge S., Saposnik G., Nilanont Y., Hachinski V.
Neglecting the difference: Does right or left matter in stroke outcome after thrombolysis?.
Stroke.
2006.
37
(8):
2066-2069.
Journal Name : Stroke
Source : Scopus
|
